Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer

The purpose of the present study was to identify a biomarker that can predict the response to preoperative chemoradiotherapy (PCRT) in esophageal cancer patients. Twenty-five serum samples collected from patents with esophageal cancer before PCRT (responder = 13, non-responder = 12) were analyzed by...

Full description

Saved in:
Bibliographic Details
Published in:Biological & pharmaceutical bulletin 2019/10/01, Vol.42(10), pp.1766-1771
Main Authors: Nambu, Madoka, Masuda, Takeshi, Ito, Shingo, Kato, Ken, Kojima, Takashi, Daiko, Hiroyuki, Ito, Yoshinori, Honda, Kazufumi, Ohtsuki, Sumio
Format: Article
Language:English
Subjects:
Aged
biomarker
Biomarkers
Biomarkers, Tumor - blood
C-reactive protein
C-Reactive Protein - analysis
Cancer
Chemoradiotherapy
Chemotherapy
Esophageal cancer
Esophageal Neoplasms - blood
Esophageal Neoplasms - therapy
Esophagus
Female
Glycoproteins
Glycoproteins - blood
Health risk assessment
Humans
Interleukin 6
Leucine
leucine-rich alpha-2-glycoprotein 1
Male
Middle Aged
Proteomics
Radiation therapy
Receptors, Interleukin-6 - blood
Serum levels
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of the present study was to identify a biomarker that can predict the response to preoperative chemoradiotherapy (PCRT) in esophageal cancer patients. Twenty-five serum samples collected from patents with esophageal cancer before PCRT (responder = 13, non-responder = 12) were analyzed by quantitative proteomics, and 248 proteins were identified. Among them, the serum levels of leucine-rich alpha-2-glycoprotein 1 (LRG1) were significantly different (p 0.8) between responder and non-responder groups. The combination of LRG1 with C-reactive protein (CRP) and soluble interleukin-6 receptor (sIL-6R), which were previously reported as biomarkers predicting PCRT response, further improved the predictive performance, providing an AUC of greater than 0.9. The present results suggest that LRG1 and its combination with CRP and sIL-6R are promising biomarker candidates to predict response to PCRT in esophageal cancer patients.
ISSN:0918-6158
1347-5215
DOI:10.1248/bpb.b19-00395